




## Panel Screening Opportunity in TNBC Models



**Dear Colleagues,**

We're offering a unique opportunity to evaluate your compound across a panel of 14 well-characterized triple-negative breast cancer (TNBC) models.

This joint screening initiative enables you to benefit from shared controls, streamlined workflows, and competitive pricing — all while generating robust, translatable efficacy data. Optional add-on services such as IHC, PK/PD, and histology are also available to deepen your insights.

EPO's expertise in TNBC modeling and drug evaluation was recently featured in an oral presentation at AACR 2025 [[Abstract](#)] highlighting our leadership in translational oncology research.

### Test the efficacy of your compound(s) in a panel of 14 TNBC PDX models

**Enrollment is now** open through August 15<sup>th</sup>


#### FEATURES

- Access to a curated panel of **14 well-characterized triple-negative breast cancer (TNBC) models**, representing diverse molecular and phenotypic profiles.
- Each model is backed by **RNA sequencing data**, mutations and tissue bank samples. Models have been pre-tested with **clinically relevant compounds**.
- Standardized **8-week study duration**, with tumor growth inhibition as the primary efficacy read-out.
- **Competitive pricing available** when selecting the full 14-model panel screen, leveraging shared controls and streamlined workflows for maximum value.
- Option to include **additional services** such as **IHC, PK/PD, and histology** and sampling (frozen, FFPE, blood) tailored to support

Please [contact us](#) directly to discuss your compound of interest, reserve your slot, or request a detailed study proposal.

Best regards,

Jens Hoffmann (CEO), Wolfgang Walther (CSO), Antje Wengner (CSO)  
EPO Berlin-Buch



### Related Talks and Publications

#### Talk AACR, Chicago 2025


- Triple negative breast cancer (TNBC) PDX models for preclinical investigation of novel therapies
- **Hoffmann J, Behrens D**  
[Abstract](#)

#### Publications

- Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.  
Heynen GJJ, Lisek K, Vogel R, **Wulf-Goldenberg A, Alcaniz J**, Montaudon E, Marangoni E, Birchmeier W. Breast Cancer Res. 2022;24(1):23 ([Weblink](#)).
- MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.  
Schwarzenbacher D, Klec C, Pasculli B, Cerik S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, **Wulf-Goldenberg A**, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M. Breast Cancer Res. 2019;21(1):20 ([Weblink](#)).

## Experimental Pharmacology & Oncology Berlin-Buch GmbH

Robert-Rössle-Str. 10, 13125 Berlin-Buch  
[www.epo-berlin.com](http://www.epo-berlin.com)



Represented by: Dr. Jens Hoffmann (CEO), Prof. Dr. Wolfgang Walther (CSO) | Register entry: Amtsgericht Berlin-Charlottenburg | Registernummer: HR B 61814 | Steuernummer: DE812180604 | Responsible for the content according to § 55 para. 2 RStV: Dr. Jens Hoffmann (CEO), Prof. Dr. Wolfgang Walther (CSO) | Address see company headquarters  
Photo credits: © crystal light/Shutterstock

[Unsubscribe](#)